← Back to patent-cliff list
Lu-177-DGUL
Tier C — Watch / tradeLu-177-DGUL
Cellbion Co Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Radiopharmaceutical
Type
Targets：PSMA
Indications (approved)：Prostate cancer, Castration-resistant prostate cancer
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Lu-177-DGUL?
Approved indications include: Prostate cancer, Castration-resistant prostate cancer.
When does the Lu-177-DGUL patent expire?
No public expiry year is available for Lu-177-DGUL yet; this page updates once verified.
How do I get a quote for Lu-177-DGUL intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06